Search - tctmd.com

Displaying 201 - 220 of 293

Sort: Relevancy | Date

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Industry News

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

May 15, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News CRT 2017

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Michael O'Riordan

February 27, 2017

News Conference News CRT 2017

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Michael O'Riordan

February 22, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

News Daily News

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

Michael O'Riordan

January 26, 2017

News Features

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Michael O'Riordan

January 24, 2017

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

Advertisement

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content